Nothing Special   »   [go: up one dir, main page]

HRP20150852T1 - Nova imunoterapija protiv tumora mozga - Google Patents

Nova imunoterapija protiv tumora mozga Download PDF

Info

Publication number
HRP20150852T1
HRP20150852T1 HRP20150852TT HRP20150852T HRP20150852T1 HR P20150852 T1 HRP20150852 T1 HR P20150852T1 HR P20150852T T HRP20150852T T HR P20150852TT HR P20150852 T HRP20150852 T HR P20150852T HR P20150852 T1 HRP20150852 T1 HR P20150852T1
Authority
HR
Croatia
Prior art keywords
peptide
amino acid
replaced
cell
antigen
Prior art date
Application number
HRP20150852TT
Other languages
English (en)
Inventor
Niels Emmerich
Oliver Schoor
Norbert Hilf
Toni Weinschenk
Claudia Trautwein
Steffen Walter
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08005889.4A external-priority patent/EP2105501B1/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of HRP20150852T1 publication Critical patent/HRP20150852T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/02—Sulfotransferases (2.8.2)
    • C12Y208/02011—Galactosylceramide sulfotransferase (2.8.2.11)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (12)

1. Peptid odabran iz skupine a) peptida koji se sastoji od odsječka aminokiseline u skladu sa SEQ ID br. 5 i b) peptida u skladu s tvrdnjom a), pri čemu su jedna ili dvije ostatne tvari aminokiseline promijenjene tako da je aminokiselina K na položaju 1 zamijenjena je bilo kojom od I, L, F, M ili Y aminokiselina V na položaju 2 zamijenjena je bilo kojom od M ili L aminokiselina F na položaju 3 zamijenjena je bilo kojom od A, Y, P, M ili S aminokiselina A na položaju 4 zamijenjena je bilo kojom od E, G, P ili T aminokiselina G na položaju 5 zamijenjena je bilo kojom od I, K, Y, N, F ili V aminokiselina I na položaju 6 zamijenjena je bilo kojom od L ili T aminokiselina P na položaju 7 zamijenjena je bilo kojom od A, Y ili H aminokiselina T na položaju 8 zamijenjena je bilo kojom od K ili E i aminokiselina V na položaju 9 zamijenjena je s L pri čemu navedeni peptid zadržava sposobnost vezivanja s molekulom glavnog kompleksa gena tkivne podudarnosti (MHC) klase I i pri čemu je navedeni peptid sposoban za stimulaciju CD8 T stanica.
2. Peptid u skladu s patentnim zahtjevom 1, pri čemu navedeni peptid uključuje nepeptidne veze između njegovih aminokiselina.
3. Peptid u skladu s patentnim zahtjevom 1 ili 2, pri čemu je navedeni peptid dio fuzijske bjelančevine koja se sastoji od N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
4. Nukleinska kiselina, koja kodira peptid u skladu s patentnim zahtjevom 1 ili 3, ili ekspresivni vektor koji eksprimira navedenu nukleinsku kiselinu.
5. Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, nukleinska kiselina ili vektor ekspresije u skladu s patentnim zahtjevom 4 za upotrebu u medicini.
6. Stanica domaćin koja nije humana embrionska matična stanica, a koja se sastoji od nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 4.
7. Stanica domaćih u skladu s patentnim zahtjevom 6, pri čemu je stanica domaćin dendritička stanica ili stanica koja prezentira antigen.
8. In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I ili II s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnog spoja koji oponaša stanicu koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1.
9. Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, nukleinska kiselina ili ekspresivni vektor u skladu s patetnim zahtjevom 4, ili stanica u skladu s patentnim zahtjevom 6 ili 7 za upotrebu u liječenju karcinoma mozga.
10. Cjepivo koje sadrži peptid u skladu s bilo kojim od patentnih zahtjeva 1 ili 2 za upotrebu u liječenju karcinoma mozga.
11. Cjepivo u skladu s patentnim zahtjevom 10 za upotrebu u skladu s patentnim zahtjevom 10, pri čemu je navedeni karcinom neki od sljedećih: astrocitom, pilocitični astrocitom, disembrioplastičan neuroepitelijalni tumor, oligodendrogliomi, ependimomi, glioblastom multiforme, miješani gliomi, oligoastrocitomi, meduloblastomi, retinoblastomi, neuroblastom, germinom, teratom, gangliogliomi, gangliocitom, centralni gangliocitom, primitivni neuroektodermalni tumori (PNET), meduloblastom, meduloepiteliom, neuroblastom, retinoblastom, ependimoblastom, tumori pinealno parenhima, pineocitom, pineoblastom, tumorni ependimalnih stanica, tumori koroidnog pleksusa, neuroepitelijalni tumori nepoznatog podrijetla, gliomatosis cerebri, astroblastom i glioblastom.
12. Upotreba peptida u skladu s patentnim zahtjevom 1 ili 2 za stvaranje i specifičnih protutijela na MHC/peptidni kompleks.
HRP20150852TT 2007-07-27 2015-08-11 Nova imunoterapija protiv tumora mozga HRP20150852T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07014797 2007-07-27
US95316107P 2007-07-31 2007-07-31
EP08005889.4A EP2105501B1 (en) 2008-03-27 2008-03-27 Novel immunotherapy against neuronal and brain tumors
EP13175457.4A EP2660248B1 (en) 2007-07-27 2008-07-25 Novel immunotherapy against brain tumors

Publications (1)

Publication Number Publication Date
HRP20150852T1 true HRP20150852T1 (hr) 2015-09-25

Family

ID=39720257

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20150820TT HRP20150820T1 (en) 2007-07-27 2015-07-28 Novel immunotherapy against brain tumors
HRP20150852TT HRP20150852T1 (hr) 2007-07-27 2015-08-11 Nova imunoterapija protiv tumora mozga

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20150820TT HRP20150820T1 (en) 2007-07-27 2015-07-28 Novel immunotherapy against brain tumors

Country Status (22)

Country Link
US (6) US9175040B2 (hr)
EP (2) EP2660248B1 (hr)
JP (2) JP6008461B2 (hr)
KR (2) KR101290892B1 (hr)
CN (2) CN101809148B (hr)
AU (1) AU2008281015B2 (hr)
BR (1) BRPI0813621A2 (hr)
CA (2) CA2863010C (hr)
CY (1) CY1117115T1 (hr)
DK (2) DK2660248T3 (hr)
EA (2) EA034800B1 (hr)
ES (2) ES2543815T3 (hr)
HK (1) HK1191022A1 (hr)
HR (2) HRP20150820T1 (hr)
HU (1) HUE027524T2 (hr)
MX (1) MX2010001086A (hr)
NZ (2) NZ592261A (hr)
PL (2) PL2660248T3 (hr)
PT (2) PT2183361E (hr)
RS (2) RS54204B1 (hr)
SI (2) SI2660248T1 (hr)
WO (1) WO2009015843A1 (hr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
RS54204B1 (en) * 2007-07-27 2015-12-31 Immatics Biotechnologies Gmbh NEW IMMUNOTHERAPY AGAINST BRAIN TUMOR
US8530429B2 (en) * 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
EP2661622B1 (en) * 2011-01-05 2017-11-08 Wisconsin Alumni Research Foundation Bystander immune suppression as a predictor for response to a vaccine
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US20180133327A1 (en) * 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
CR20210232A (es) * 2015-03-17 2022-06-24 Immatics Biotechnologies Gmbh NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3919507A3 (en) 2015-07-01 2022-01-12 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PE20231014A1 (es) * 2015-07-06 2023-07-05 Immatics Biotechnologies Gmbh Nuevos peptidos y combinacion de peptidos para usar en inmunoterapia contra el cancer esofagico y otros canceres
GB201512369D0 (en) * 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
PE20181535A1 (es) 2015-12-16 2018-09-26 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno
KR20190031573A (ko) * 2016-08-02 2019-03-26 난트셀, 인크. 수지상 세포들의 형질주입 및 그 방법들(transfection of dendritic cells and methods therefor)
WO2018055060A1 (en) 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
AU2018214556A1 (en) 2017-02-01 2019-08-15 Modernatx, Inc. Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides
EP3609530A1 (en) * 2017-04-10 2020-02-19 Immatics Biotechnologies GmbH Peptides and combination thereof for use in the immunotherapy against cancers
CN118888004A (zh) 2017-10-10 2024-11-01 磨石生物公司 使用热点进行的新抗原鉴别
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
EP4405464A2 (en) * 2021-09-21 2024-07-31 The University of Chicago Methods and composition using patient-derived autologous neoantigens for treating cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
JP2530801B2 (ja) 1978-12-22 1996-09-04 バイオゲン インコーポレイテッド 組換えｄｎａ分子
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
JPS6081130A (ja) * 1983-10-07 1985-05-09 Fujisawa Pharmaceut Co Ltd 抗ｈｌａ−ａ２抗体およびそれを産生するハイブリド−マ
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5651972A (en) * 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
US5202666A (en) * 1991-01-18 1993-04-13 Net/Tech International Inc. Method and apparatus for enhancing hygiene
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
AU696118B2 (en) * 1995-04-07 1998-09-03 Regents Of The University Of California, The Antibodies for the detection of HLA-G
EP0879282B1 (en) 1996-01-17 2003-07-02 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE19739089A1 (de) * 1997-09-06 1999-03-11 Hella Kg Hueck & Co Scheinwerfer für Fahrzeuge
CA2304208A1 (en) * 1997-09-19 1999-03-25 Dana-Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
AU5284200A (en) * 1999-06-03 2000-12-28 Cold Spring Harbor Laboratory Substrate trapping protein tyrosine phosphatases
US20030118585A1 (en) 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
US6455026B1 (en) 2001-03-23 2002-09-24 Agy Therapeutics, Inc. Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
JP2003012544A (ja) * 2001-03-27 2003-01-15 Kouji Egawa 癌予防・治療剤
US20050260132A1 (en) * 2001-10-17 2005-11-24 Daniel Chin Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
AU2002365187A1 (en) * 2001-11-07 2003-07-24 Mannkind Corporation Epitope synchronization in antigen presenting cells
WO2003042661A2 (en) * 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7236577B2 (en) * 2002-11-14 2007-06-26 International Business Machines Corporation Call screening system and method
KR100494979B1 (ko) * 2003-07-14 2005-06-14 주식회사 정우인터내셔날 조직 절편 보호 및 해상력 증진용 액상 커버 슬립, 그제조용 조성물, 그로부터 제조된 커버슬립을 구비한슬라이드 구조체 및 그 제조방법
US7050785B2 (en) * 2003-12-08 2006-05-23 Research In Motion Limited Apparatus and method of explicit indication of call from emergency call centre
AU2005206389A1 (en) 2004-01-27 2005-08-04 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US7231200B2 (en) * 2004-09-30 2007-06-12 Nevin Jenkins Personal emergency communication system
US7315736B2 (en) * 2004-09-30 2008-01-01 Jenkins Nevin C Personal emergency communication system
EP1760089B1 (en) 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
PT1760088E (pt) 2005-09-05 2008-05-14 Immatics Biotechnologies Gmbh Péptidos associados a tumores que se ligam promiscuamente a moléculas de antigénio leucocitário humano (hla) de classe ii
RS54204B1 (en) * 2007-07-27 2015-12-31 Immatics Biotechnologies Gmbh NEW IMMUNOTHERAPY AGAINST BRAIN TUMOR
DE602008000891D1 (de) * 2008-04-30 2010-05-12 Immatics Biotechnologies Gmbh Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
US10046046B2 (en) * 2014-06-05 2018-08-14 Victoria Link Limited Amino sphingoglycolipid analogues

Also Published As

Publication number Publication date
CN103911358B (zh) 2017-03-01
US20230241111A1 (en) 2023-08-03
KR101290892B1 (ko) 2013-07-31
CN101809148B (zh) 2014-07-16
EA201000209A1 (ru) 2011-02-28
KR20100040874A (ko) 2010-04-21
PL2660248T3 (pl) 2015-11-30
US20190321405A1 (en) 2019-10-24
DK2660248T3 (en) 2015-09-07
WO2009015843A1 (en) 2009-02-05
ES2543815T3 (es) 2015-08-24
EP2660248B1 (en) 2015-06-10
AU2008281015A2 (en) 2010-05-27
AU2008281015B2 (en) 2012-07-26
JP2010534464A (ja) 2010-11-11
CY1117115T1 (el) 2017-04-05
SI2660248T1 (sl) 2015-10-30
RS54204B1 (en) 2015-12-31
JP6008461B2 (ja) 2016-10-19
HK1191022A1 (en) 2014-08-29
US20200345777A1 (en) 2020-11-05
EP2183361A1 (en) 2010-05-12
PT2183361E (pt) 2015-09-11
PL2183361T3 (pl) 2015-10-30
NZ582824A (en) 2012-07-27
EA034800B1 (ru) 2020-03-23
US11986497B2 (en) 2024-05-21
US20090123489A1 (en) 2009-05-14
JP2013226145A (ja) 2013-11-07
US20160175357A1 (en) 2016-06-23
US11648276B2 (en) 2023-05-16
US9175040B2 (en) 2015-11-03
CA2694808C (en) 2015-10-13
EP2183361B1 (en) 2015-06-10
SI2183361T1 (sl) 2015-09-30
JP5738348B2 (ja) 2015-06-24
CN103911358A (zh) 2014-07-09
EP2660248A1 (en) 2013-11-06
CA2863010C (en) 2017-01-24
US10709735B2 (en) 2020-07-14
ES2546610T3 (es) 2015-09-25
US10434120B2 (en) 2019-10-08
CA2694808A1 (en) 2009-02-05
CA2863010A1 (en) 2009-02-05
US20190076477A1 (en) 2019-03-14
NZ592261A (en) 2012-09-28
PT2660248E (pt) 2015-10-12
EA029831B1 (ru) 2018-05-31
KR101317989B1 (ko) 2013-10-14
MX2010001086A (es) 2010-04-09
KR20120025014A (ko) 2012-03-14
BRPI0813621A2 (pt) 2017-05-09
CN101809148A (zh) 2010-08-18
HRP20150820T1 (en) 2015-09-11
EA201791519A1 (ru) 2018-03-30
DK2183361T3 (en) 2015-07-27
HUE027524T2 (en) 2016-11-28
RS54147B1 (en) 2015-12-31
AU2008281015A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
HRP20150852T1 (hr) Nova imunoterapija protiv tumora mozga
HRP20201015T1 (hr) Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20201467T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
JP2010534463A5 (hr)
HRP20191009T1 (hr) Personalizirana imunoterapija protiv nekoliko neuronalnih i moždanih tumora
JP2010534464A5 (hr)
HRP20192262T1 (hr) Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc)
HRP20150300T4 (hr) Novi i snažni mhc-razred ii peptidi derivirani iz survivina i neurokana
JP2012509071A5 (hr)
JP2011520436A5 (hr)
JP2020191862A5 (hr)
JP2020182458A5 (hr)
AR121383A2 (es) Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
JP2020198875A5 (hr)
HRP20210076T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma
JP2012504393A5 (hr)
EA201892021A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
EA201891759A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
JP2013521789A5 (hr)
JP2017502076A5 (hr)
CN103037898B (zh) 呼吸道合胞病毒抗原组合物和方法
JP2019515650A5 (hr)
JP2014523406A5 (hr)
HRP20151313T1 (hr) Nova imunoterapija protiv neuronskih tumora i tumora mozga